Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

2.940 -0.210 (-6.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
News headline image
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals ↗
 
Via Benzinga
News headline image
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios. ↗
Via The Motley Fool
News headline image
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Peering Into Recursion Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
NVIDIA Invested in These 2 AI Stocks, Should You?
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One ↗
Jim Cramer praises Reddit, Inc. but warns of auto parts made in China. Recursion Pharmaceuticals and Dow Inc. face challenges. Super Micro Computer sells due to accounting irregularities. 
Via Benzinga
Topics Stocks
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
2 Innovative Stocks That Could Deliver Outsize Returns ↗
Via The Motley Fool
News headline image
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars ↗
Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes ↗
Nvidia has disclosed an investment in Applied Digital, a digital infrastructure provider. Nvidia stock dipped while APLD stock rose. 
Via Investor's Business Daily
News headline image
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
10 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? ↗
In an environment where the typical small biotech name is riskier than not, this one is curiously different. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
News headline image
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock ↗
This company stands to benefit from a shifting pharmaceutical industry landscape. 
Via The Motley Fool
News headline image
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Stocks Could Soar in 2025 ↗
The key word here is "could." 
Via The Motley Fool
News headline image
Cathie Wood Is Betting on This AI Stock: Is It a Buy? ↗
Wood has a stake in this stock, but it's hardly an "all-in" bet. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? ↗
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.